三种DAAs方案治疗慢性丙型肝炎患者两年随访研究*

doi:10.3969/j.issn.1672-5069.2024.01.009

摘要/Abstract

摘要： 目的分析不同直接抗病毒药物(DAAs)治疗慢性丙型肝炎(CHC)患者的疗效,随访观察两年结果。方法 2018年1月～2020年12月我院收治的CHC患者123例,其中接受索磷布韦/维帕他韦(SOF/VEL)治疗52例,接受艾尔巴韦/格拉瑞韦(EBR/GZR)治疗43例,接受来迪派韦/索磷布韦(LDV/SOF)治疗28例,均连续治疗12 w,随访24 m。采用实时荧光定量RT-PCR法检测血清HCV RNA,比较不同方案治疗患者快速病毒学应答(RVR)、早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)情况。结果 SOF/VEL、EBR/GZR和LDV/SOF治疗患者RVR分别为96.2%、93.0%和92.9%,EVR分别为98.1%、97.7%和96.4%,ETVR和SVR均为100.0%,组间疗效比较,差异均无统计学意义(均P＞0.05);在治疗过程中,SOF/VEL、EBR/GZR和LDV/SOF治疗组出现恶心、乏力和头晕等不良反应发生率分别为13.5%、11.6%和21.4%,组间比较,差异无统计学意义(P＞0.05);在三组获得SVR者,分别有45例、36例和23例完成2年监测随访,结果均未发生病毒学复发和病情反复情况,也未出现肝癌发生。结论由于我国CHC患者以GT1b基因型感染为主,应用SOF/VEL、EBR/GZR或LDV/SOF抗病毒治疗效果均好,较长期的观察病情无反复。

关键词: 慢性丙型肝炎, 直接抗病毒药物, 持续病毒学应答, 治疗

Abstract: Objective The aim of this study was to investigate the twenty-four month follow-up efficacy for patients with chronic hepatitis C (CHC) after sustained virological response (SVR) to different direct-acting antiviral agents (DAAs) treatment regimen. Methods 123 patients with CHC were enrolled in our hospital between January 2018 and December 2020, and were divided into three groups, receiving sofosbuvir/velpatasvir (SOF/VEL) in 52 cases, elbasvir/grazoprevir (EBR/GZR) in 43 cases, and ledipasvir/sofosbuvir (LDV/SOF) in 28 cases. The antiviral regimen lasted for 12 weeks and all patients were followed-up for 24 weeks. Serum HCV RNA loads were detected by real-time fluorescence quantitative RT-PCR. The rapid virological response (RVR), early virological response (EVR), end of treatment virological response (ETVR) and SVR were recorded in three groups. Results The RVR in SOF/VEL-, EBR/GZR- and LDV/SOF-treated patients were 96.2%, 93.0% and 92.9%, the EVR were 98.1%, 97.7% and 96.4%, the ETVR and SVR in all patients were 100.0%, not significantly different among the three groups ( all P＞0.05); during the treatment, the incidences of untoward effects, such as nausea, fatigue and dizziness, in the three groups were 13.5%, 11.6% and 21.4%, not significant different among them (P＞0.05); 7, 7 and 5 patients with SVR in the three groups lost, all other patients with SVR were followed-up for 24 months, and no relapse or liver cancer were found. Conclusion All the antiviral regimen, with different DAAs have good efficacy as HCV GT1b infection is common in China, and no relatively long-term relapse.

Key words: Hepatitis C, Direct-acting antiviral agents, Sustained virological response, Therapy

王焱, 韩军, 杨美蓉. 三种DAAs方案治疗慢性丙型肝炎患者两年随访研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 32-35.

Wang Yan, Han Jun, Yang Meirong. Twenty-four month follow-up for patients with chronic hepatitis C after sustained virological response to different DAAs treatment regimen[J]. Journal of Practical Hepatology, 2024, 27(1): 32-35.

参考文献

[1] 丁国伟,庞琳,王晓春,等.2017-2019年哨点医院丙型肝炎基线特征及治疗现况分析.中华肝脏病杂志,2020,28(10):844-849.
[2] Townshend-Bulson L, Roik E, Barbour Y, et al. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. PLoS One, 2021, 16(12):e0260970.
[3] 柴晓哲,朱霞峰,骆成林,等.泛基因型与特异基因型DAAs方案精准治疗基因1b型慢性丙型肝炎患者疗效对比分析.实用肝脏病杂志,2022,25(3):355-358.
[4] Wedemeyer H, Di Marco V, Garcia-Retortillo M, et al. Global real-world evidence of sofosbuvir/velpatasvir as a highly effective treatment and elimination tool in people with hepatitis C infection experiencing mental health disorders. Viruses, 2022, 14(11):2493-2501.
[5] Sulkowski MS, Moon JS, Sherman KE, et al. A pragmatic, randomized controlled trial of oral antivirals for the treatment of chronic hepatitis C: The PRIORITIZE Study. Hepatology, 2021, 74(6):2952-2964.
[6] Banga J, Nizami S, Slim J, et al. Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population. Medicine (Baltimore), 2020, 99(11):e19140.
[7] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2019年更新版.实用肝脏病杂志,2020,23(1):S33-52.
[8] 屈凌霄,施阳,陈恺韵,等.上海市2014-2019年丙型肝炎综合监测分析.中华流行病学杂志,2021,42(4):626-631.
[9] Karmarkar T, Rodriguez-Watson CV, Watson E, et al. Value of triage treatment strategies to distribute hepatitis C direct-acting antiviral agents in an integrated healthcare system: A cost-effectiveness analysis. Value Health, 2022, 25(9):1499-1509.
[10] Matthew AN, Zephyr J, Nageswara Rao D, et al. Avoiding drug resistance by substrate envelope-guided design: Toward potent and robust HCV NS3/4A protease inhibitors. mBio, 2020, 11(2):172-191.
[11] Bobardt M, Ramirez CM, Baum MM, et al. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLoS One, 2021, 16(5):e0251934.
[12] Ahmed HR, Waly NGFM, Abd El-Baky RM, et al. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS One, 2021, 16(4):e0249770.
[13] AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus Infection. Clin Infect Dis, 2018, 67(10):1477-1492.
[14] Stafford F, Dore GJ, Clackett S, et al. Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. Med J Aust, 2021, 215(7):332-333.
[15] Li J, Wu DB, Jiang W, et al. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study. Medicine (Baltimore), 2020, 99(43):e22726.
[16] Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol, 2021, 93(11):6247-6256.
[17] Hüppe D, Stoehr A, Klinker H, et al. Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/ GZR): results from the German hepatitis C registry (DHC-R). J Hepatol, 2020, 73(1):342-343.
[18] Jang ES, Kim KA, Kim YS, et al. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. Korean J Intern Med, 2021, 36(S1):1-8.
[19] Chiu HC, Chiu YC, Yang EH, et al. Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. J Formos Med Assoc, 2021, 120(3):983-990.
[20] Lin T, Wang X, Gao H, et al. Effect of hemodialysis on efficacy and pharmacokinetics of sofosbuvir coformulated with either daclatasvir or ledipasvir in patients with end-stage renal disease. Blood Purif, 2020, 49(6):692-699.
[21] Shiner B, Huybrechts K, Gui J, et al. Comparative effectiveness of direct-acting antivirals for posttraumatic stress disorder in veterans affairs patients with hepatitis C virus infection. Am J Epidemiol, 2022, 191(9):1614-1625.
[22] Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol, 2017, 67(6):1204-1212.

三种DAAs方案治疗慢性丙型肝炎患者两年随访研究^*

Twenty-four month follow-up for patients with chronic hepatitis C after sustained virological response to different DAAs treatment regimen

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈从新, 陈曦, 王莉苹, 赵秋香, 刘颖, 周海洋. 糖皮质激素在肝病治疗中的应用[J]. 实用肝脏病杂志, 2024, 27(3): 321-323.
[2]	赵玉雯, 朱传龙. 肝硬化营养不良及肌少症治疗研究进展[J]. 实用肝脏病杂志, 2024, 27(3): 324-328.
[3]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[4]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[5]	程艳洁, 王鹏飞, 李峻. 水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 349-352.
[6]	徐秋萍, 黄彬, 陈敏, 余静. 泼尼松与泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者外周血MDSCs百分比、肝组织白细胞介素-35和血清CD38水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 374-377.
[7]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[8]	李菊兰, 张华堂, 郑怡娟, 余雪平, 邓勇, 苏智军. 恩替卡韦联合扶正化瘀片治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 402-405.
[9]	蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东. 基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(3): 406-409.
[10]	闫振, 赵博文, 林国英, 殷和良. 影像学三维可视化技术指导肝切除术治疗肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 438-441.
[11]	李玮健, 刘昕, 舒红艳. 超声引导下聚桂醇与无水乙醇注射硬化治疗肝囊肿患者疗效比较研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 450-453.
[12]	王苓入, 苏虹, 郝晓炜, 李娜. 超声引导下PTGD联合聚桂醇硬化治疗单纯性肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 454-457.
[13]	徐旭, 施漪雯, 范建高. 肝豆状核变性治疗现状与展望^*[J]. 实用肝脏病杂志, 2024, 27(3): 477-480.
[14]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[15]	李兴泉, 杨春, 李诗源, 翁凯, 彭麟. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 177-180.